Global Duchenne Muscular Dystrophy (DMD) Drugs Market Outlook to 2023: A $4.11 Billion Opportunity

World News: . []

Dublin, Nov. 09, 2018 (GLOBE NEWSWIRE) -- The report has been added to offering. The global duchenne muscular dystrophy (DMD) drugs market size is expected to reach USD 4.11 billion by 2023, expanding at a CAGR of 41.3% during the forecast period. Several factors such as emergence of mutation-specific therapies, growing target population, and favorable government initiatives are driving the market.The DMD therapeutics market has only three approved products - Exondys51, Translarna, and Emflaza. Increasing uptake of mutation-targeted therapies is likely to boost the sales of branded drugs. However, stringent regulatory procedures and lack of standardized protocol for determination of clinical efficacy are key challenges for the market.Exon-skipping platform is estimated to hold about 45% of the market share by 2023, driven by increasing adoption of Exondys51 and impending approval of golodirsen and casimersen. Mutation-specific therapies, such as Translarna, are anticipated to face limited adoption due to premium pricing. Associated adverse effects of steroid therapy make them a less favored treatment option.The DMD drugs market is projected to become intensely competitive in medium- to long-term. The sector has witnessed delays and denials of several key products by the U.S. FDA due to insufficient trials. Raxone (by Santhera) and Givinostat (by Italfarmaco) remain the most strategically significant R&D pipeline assets for the DMD market, with good possibility of regulatory approval during the forecast period.Launch of late-stage pipeline products is poised to alter the DMD therapeutic landscape in the near future. Several novel mechanisms of action, such as NF-?B inhibition, myostatin inhibition, and gene therapy are under investigation. Other drug classes, such as exon-skipping and mutation-suppression, are expected to gain traction over the forecast period, supported by rising adoption of these therapeutics.Milo Biotechnology is one of the first companies to venture into gene therapy for DMD. Company's investigational therapy uses an adeno-associated virus as a myostatin inhibitor and is in early stages of development. Wave Life Science's pipeline product is likely to perform 25 times better in terms of clinical efficacy than the existing exon-skipping drugs.


CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs , Musculoskeletal Disorders Drugs

More news and information about Research and Markets

Published By:

Globe Newswire: 12:27 GMT Friday 9th November 2018

Published: .

Search for other references to "global" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us